Tng tc ca Ginkgo Biloba vi thuc iu tr Trong trng hp bn ang dng bt k loi thuc no sau y, hy tham kho kin t bc s hoc dc s trc khi bt u s dng thuc b no Ginkgo Biloba
Symptoms of primary infection include flu-like symptoms, such as: Fever Body aches Sore throat Headache Swollen lymph nodes, usually near where the virus entered your body You may also get a single, painful, fluid-filled blister or a cluster of blisters on or around your lips or under your nose

Category : HUMAN PRESCRIPTION DRUG LABEL DEA Schedule : none Marketing Status : New Drug Application INGREDIENTS AND APPEARANCE LABELER - Hikma Pharmaceuticals USA Inc.(001230762) PRINCIPAL DISPLAY PANEL NDC 0143-9621-01 1 mL Vial Cyanocobalamin Injection, USP Rx only 1,000 mcg/mL For IM or SC use ONLY Protect from light Contains Benzyl Alcohol NDC 0143-9621-25 Rx only Cyanocobalamin Injection, USP 1,000 mcg/mL For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative 25 x 1 mL Vials PRINCIPAL DISPLAY PANEL NDC 0143-9620-01 10 mL Multiple Dose Vial Cyanocobalamin Injection, USP Rx only 10,000 mcg per 10 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative NDC 0143-9620-10 Rx only Cyanocobalamin Injection, USP 10,000 mcg per 10 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative 10 x 10 mL Multiple Dose Vials PRINCIPAL DISPLAY PANEL NDC 0143-9619-01 30 mL Multiple Dose Vial Cyanocobalamin Injection, USP Rx only 30,000 mcg per 30 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative NDC 0143-9619-10 Rx only Cyanocobalamin Injection, USP 30,000 mcg per 30 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative 10 x 30 mL Multiple Dose Vials NDC 0143-9619-01 Rx only Cyanocobalamin Injection, USP 30,000 mcg per 30 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative 1 x 30 mL Multiple Dose Vials PRINCIPAL DISPLAY PANEL

Metformin and SGLT2 inhibitors generally pose lower interaction risk but still require dose review